With Brazil’s National Cancer Institute estimating 17,010 new cases in 2023, cervical cancer is the third leading cause of morbidity among Brazil’s female population.
Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL
The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to
December 31, 2024